Hardman Johnston Global Advisors reported Q1 2026 performance for its Large Cap Equity Strategy, posting a modest 0.68% gross return against a significant -4.33% benchmark decline. The fund's outperformance relative to its index reflects defensive positioning and selective stock picking, though absolute gains remain compressed in a volatile market environment.
The strategy's conviction holding in IQVIA Holdings (IQV) signals continued confidence in contract research and clinical trial services despite near-term macroeconomic headwinds. This positioning suggests the fund manager views healthcare outsourcing as relatively resilient, even as growth stocks face valuation pressure. The maintained position indicates belief in structural demand for clinical trial support services independent of near-term equity market direction.
The outperformance narrative—beating a sharply negative benchmark—likely reflects underweight exposure to growth-heavy technology positions and rotation toward healthcare and defensive sectors. This mirrors institutional sentiment favoring quality and stability during periods of market correction, rather than a bullish inflection point.
Sector implication: The Health Care sector benefits from its counter-cyclical characteristics in equity downturns. Fund positioning in contract research organizations suggests institutional conviction that healthcare infrastructure spending remains durable across economic cycles, though the modest absolute returns indicate limited enthusiasm for aggressive allocation growth in the near term.